1-3 of 3
José Thomas
Close
Sort by
Journal Articles

Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma

Clinical Trials & Observations
Elizabeth C. Moser, Evert M. Noordijk, Flora E. van Leeuwen, Saskia le Cessie, Joke W. Baars, José Thomas, Patrice Carde, Jacobus H. Meerwaldt, Martine van Glabbeke, Hanneke C. Kluin-Nelemans
Journal: Blood
Blood (2006) 107 (7): 2912–2919.
https://doi.org/10.1182/blood-2005-08-3392
Published: 2006
Journal Articles

Four ABVD and Involved-Field Radiotherapy in Unfavorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-U Trial.

Christophe Ferme, MD, Marine Diviné, MD, Andrej Vranovsky, MD, Frank Morschhauser, MD, Réda Bouabdallah, MD, Jean Gabarre, MD, Aspasia Bastard-Stamatoullas, MD, Richard Delarue, MD, Vittorina Zagonel, MD, Jérôme Jaubert, MD, Anton Hagenbeek, MD, Mark Henri H. Kramer, MD, Chantal Rieux, José Thomas, MD, Michel Henry-Amar, MD
Journal: Blood
Blood (2005) 106 (11): 813.
https://doi.org/10.1182/blood.V106.11.813.813
Published: 2005
Journal Articles

Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation

Clinical Trials & Observations
Karoline Spaepen, Sigrid Stroobants, Patrick Dupont, Peter Vandenberghe, Johan Maertens, Guy Bormans, José Thomas, Jan Balzarini, Christine De Wolf-Peeters, Luc Mortelmans, Gregor Verhoef
Journal: Blood
Blood (2003) 102 (1): 53–59.
https://doi.org/10.1182/blood-2002-12-3842
Published: 2003